{"id":63430,"date":"2026-03-05T12:28:56","date_gmt":"2026-03-05T06:58:56","guid":{"rendered":"https:\/\/matribhumisamachar.com\/en\/2026\/03\/05\/cosmo-announces-strategic-rd-collaboration-to-advance-ai-based-detection-of-early-neoplasia-in-barretts-esophagus\/"},"modified":"2026-03-20T09:27:29","modified_gmt":"2026-03-20T03:57:29","slug":"cosmo-announces-strategic-rd-collaboration-to-advance-ai-based-detection-of-early-neoplasia-in-barretts-esophagus","status":"publish","type":"post","link":"https:\/\/matribhumisamachar.com\/en\/2026\/03\/05\/cosmo-announces-strategic-rd-collaboration-to-advance-ai-based-detection-of-early-neoplasia-in-barretts-esophagus\/","title":{"rendered":"Cosmo Announces Strategic R&amp;D Collaboration to Advance AI-Based Detection of Early Neoplasia in Barrett&#8217;s Esophagus"},"content":{"rendered":"<p style=\"text-align: justify;\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/api.newsfilecorp.com\/newsinfo\/286350\/511\" width=\"2\" height=\"2\" \/><\/p>\n<p style=\"text-align: justify;\">Dublin, Ireland&#8211;(Newsfile Corp. &#8211; March 5, 2026) &#8211; Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (\u201cCosmo\u201d) today announced a strategic Research and Development Agreement with Amsterdam UMC and Eindhoven University of Technology to develop and clinically validate an artificial intelligence (AI)-based computer-aided detection (CADe) system for the identification of early neoplasia in Barrett\u2019s esophagus. The collaboration represents an important step in expanding the clinical scope of Cosmo\u2019s GI Genius\u2122 platform beyond colorectal cancer screening into upper gastrointestinal (GI) indications.<\/p>\n<p style=\"text-align: justify;\">Barrett&#8217;s oesophagus is a precancerous condition in which the pink, flat lining of the oesophagus (the tube that connects the mouth to the stomach) becomes damaged by acid reflux. This causes the lining to thicken and turn red. It affects millions of patients worldwide and increases the risk of esophageal adenocarcinoma, a type of cancer that starts in the esophagus. Detecting early neoplasia during upper GI endoscopy remains a significant clinical challenge, where AI-assisted tools may help physicians identify subtle abnormalities in real time.<\/p>\n<p style=\"text-align: justify;\">Over time, the program may support the development of additional AI applications within the GI Genius\u2122 ecosystem, further expanding the platform\u2019s clinical capabilities in upper gastrointestinal endoscopy.<\/p>\n<p style=\"text-align: justify;\">Through this collaboration, the parties will combine clinical expertise, imaging research capabilities and advanced engineering know how to curate high quality datasets, develop and train AI algorithms, and conduct structured clinical validation in specialized centers. The initiative is expected to generate one of the most comprehensive curated datasets for AI development in Barrett\u2019s esophagus.<\/p>\n<p style=\"text-align: justify;\">Cosmo will lead the industrialization and regulatory pathway, ensuring the system is developed in accordance with applicable global quality, safety and cybersecurity standards and designed for seamless integration into the GI Genius\u2122 platform. The program is intended to support future regulatory submissions in both Europe and the United States, subject to applicable approvals.<\/p>\n<p style=\"text-align: justify;\">This initiative further strengthens the GI Genius\u2122 platform and supports Cosmo\u2019s \u201cVision 2030\u201d strategy to expand its AI driven clinical innovation across multiple gastrointestinal indications, reinforcing the Company\u2019s long-term commitment to advancing AI supported endoscopy and building a scalable ecosystem of AI applications.<\/p>\n<p style=\"text-align: justify;\"><strong>Giovanni Di Napoli, CEO of Cosmo, commented:<\/strong> <em>\u201cThis collaboration reflects our ambition to expand AI assisted endoscopy beyond colorectal applications. GI Genius\u2122 has already transformed the way physicians detect colorectal lesions, and our goal is to extend the power of this platform across the broader spectrum of gastrointestinal diseases. By combining the clinical leadership of Amsterdam UMC and the engineering excellence of TU Eindhoven with Cosmo\u2019s experience in developing and scaling regulated medical software, we are advancing the next generation of AI tools designed to support physicians in real time during endoscopy.\u201d<\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Prof. Jacques Bergman, Professor of Gastrointestinal Endoscopy at Amsterdam UMC, said:<\/strong> <em>\u201cFor many years, our team has focused on improving early detection and treatment of esophageal neoplasia. Artificial intelligence is opening a new chapter in our field, offering the potential to detect subtle abnormalities that were previously very difficult to recognize systematically in the Barrett\u2019s esophagus surveillance program. By joining forces with Eindhoven\u2019s engineering researchers and Cosmo\u2019s ability to translate advanced technology into robust clinical tools, we are creating a pathway that could bring meaningful improvements to patient care.\u201d<\/em><\/p>\n<p style=\"text-align: justify;\"><b>About Cosmo <\/b><br \/>\nCosmo is a life sciences company focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). We design, develop, and manufacture advanced solutions that address critical medical needs and raise the standard of care. Our technologies are trusted by leading global pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. Guided by our purpose \u2013 Building Health Confidence \u2013 our mission is to empower patients, healthcare professionals, and partners by innovating at the intersection of science and technology. Founded in 1997, Cosmo is headquartered in Dublin, Ireland, with offices in San Diego (USA), and in Lainate, Rome, and Catania (Italy). For more information, visit\u00a0<a title=\"http:\/\/www.cosmohealthconfidence.com\" href=\"https:\/\/api.newsfilecorp.com\/redirect\/0p3LRIkkoa\">www.cosmohealthconfidence.com<\/a>.<\/p>\n<p style=\"text-align: justify;\"><b> Financial calendar <\/b><\/p>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td valign=\"top\">Full Year 2025 Results, Annual Report and ESG Report<\/p>\n<p>Jefferies Biotech Beach Summit, Miami<\/p>\n<p>Ordinary Annual General Meeting of Shareholders<\/td>\n<td valign=\"top\">March 9, 2026<\/p>\n<p>March 11, 2026<\/p>\n<p>April 10, 2026<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">Van Lanschot Kempen Life Science Conference, Amsterdam<\/td>\n<td valign=\"top\">April 16, 2026<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">TP ICAP Conference, Paris<\/td>\n<td valign=\"top\">May 7, 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div style=\"text-align: justify;\">\n<p><b>For further information, please contact: <\/b><br \/>\n<a href=\"mailto:investor.relations@cosmohc.com\">investor.relations@cosmohc.com<\/a><\/p>\n<\/div>\n<p style=\"text-align: justify;\"><b>Attachments<\/b><br \/>\n<a href=\"https:\/\/api.newsfilecorp.com\/redirect\/RYpQoFOODZ\" target=\"_blank\" rel=\"noopener\">PDF &#8211; English<\/a><\/p>\n<p style=\"text-align: justify;\">To view the source version of this press release, please visit <a href=\"https:\/\/api.newsfilecorp.com\/redirect\/WAVLpiMMG5\">https:\/\/www.newsfilecorp.com\/release\/286350<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dublin, Ireland&#8211;(Newsfile Corp. &#8211; March 5, 2026) &#8211; Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (\u201cCosmo\u201d) today announced a strategic Research and Development Agreement with Amsterdam UMC and Eindhoven University of Technology to develop and clinically validate an artificial intelligence (AI)-based computer-aided detection (CADe) system for the identification of early neoplasia in Barrett\u2019s esophagus. The &hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[32016],"tags":[29512],"class_list":["post-63430","post","type-post","status-publish","format-standard","","category-press-releases","tag-cosmo-pharmaceuticals-n-v"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.8.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Cosmo Announces Strategic R&amp;D Collaboration to Advance AI-Based Detection of Early Neoplasia in Barrett&#039;s Esophagus - Matribhumi Samachar English<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/matribhumisamachar.com\/en\/2026\/03\/05\/cosmo-announces-strategic-rd-collaboration-to-advance-ai-based-detection-of-early-neoplasia-in-barretts-esophagus\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cosmo Announces Strategic R&amp;D Collaboration to Advance AI-Based Detection of Early Neoplasia in Barrett&#039;s Esophagus - Matribhumi Samachar English\" \/>\n<meta property=\"og:description\" content=\"Dublin, Ireland&#8211;(Newsfile Corp. &#8211; March 5, 2026) &#8211; Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (\u201cCosmo\u201d) today announced a strategic Research and Development Agreement with Amsterdam UMC and Eindhoven University of Technology to develop and clinically validate an artificial intelligence (AI)-based computer-aided detection (CADe) system for the identification of early neoplasia in Barrett\u2019s esophagus. The &hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/matribhumisamachar.com\/en\/2026\/03\/05\/cosmo-announces-strategic-rd-collaboration-to-advance-ai-based-detection-of-early-neoplasia-in-barretts-esophagus\/\" \/>\n<meta property=\"og:site_name\" content=\"Matribhumi Samachar English\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-05T06:58:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-20T03:57:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/api.newsfilecorp.com\/newsinfo\/286350\/511\" \/>\n<meta name=\"author\" content=\"Saransh Kanaujia\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Saransh Kanaujia\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/2026\/03\/05\/cosmo-announces-strategic-rd-collaboration-to-advance-ai-based-detection-of-early-neoplasia-in-barretts-esophagus\/\",\"url\":\"https:\/\/matribhumisamachar.com\/en\/2026\/03\/05\/cosmo-announces-strategic-rd-collaboration-to-advance-ai-based-detection-of-early-neoplasia-in-barretts-esophagus\/\",\"name\":\"Cosmo Announces Strategic R&amp;D Collaboration to Advance AI-Based Detection of Early Neoplasia in Barrett's Esophagus - Matribhumi Samachar English\",\"isPartOf\":{\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#website\"},\"datePublished\":\"2026-03-05T06:58:56+00:00\",\"dateModified\":\"2026-03-20T03:57:29+00:00\",\"author\":{\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1\"},\"breadcrumb\":{\"@id\":\"https:\/\/matribhumisamachar.com\/en\/2026\/03\/05\/cosmo-announces-strategic-rd-collaboration-to-advance-ai-based-detection-of-early-neoplasia-in-barretts-esophagus\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/matribhumisamachar.com\/en\/2026\/03\/05\/cosmo-announces-strategic-rd-collaboration-to-advance-ai-based-detection-of-early-neoplasia-in-barretts-esophagus\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/2026\/03\/05\/cosmo-announces-strategic-rd-collaboration-to-advance-ai-based-detection-of-early-neoplasia-in-barretts-esophagus\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/matribhumisamachar.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cosmo Announces Strategic R&amp;D Collaboration to Advance AI-Based Detection of Early Neoplasia in Barrett&#8217;s Esophagus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#website\",\"url\":\"https:\/\/matribhumisamachar.com\/en\/\",\"name\":\"Matribhumi Samachar English\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/matribhumisamachar.com\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1\",\"name\":\"Saransh Kanaujia\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g\",\"caption\":\"Saransh Kanaujia\"},\"description\":\"Saransh Kanaujia is currently editor of Matribhumi Samachar Group. He earlier worked with Hindusthan Samachar News Agency. He is also associated with many organizations.\",\"sameAs\":[\"https:\/\/matribhumisamachar.com\/en\"],\"url\":\"https:\/\/matribhumisamachar.com\/en\/author\/matribhumisamachar\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cosmo Announces Strategic R&amp;D Collaboration to Advance AI-Based Detection of Early Neoplasia in Barrett's Esophagus - Matribhumi Samachar English","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/matribhumisamachar.com\/en\/2026\/03\/05\/cosmo-announces-strategic-rd-collaboration-to-advance-ai-based-detection-of-early-neoplasia-in-barretts-esophagus\/","og_locale":"en_US","og_type":"article","og_title":"Cosmo Announces Strategic R&amp;D Collaboration to Advance AI-Based Detection of Early Neoplasia in Barrett's Esophagus - Matribhumi Samachar English","og_description":"Dublin, Ireland&#8211;(Newsfile Corp. &#8211; March 5, 2026) &#8211; Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (\u201cCosmo\u201d) today announced a strategic Research and Development Agreement with Amsterdam UMC and Eindhoven University of Technology to develop and clinically validate an artificial intelligence (AI)-based computer-aided detection (CADe) system for the identification of early neoplasia in Barrett\u2019s esophagus. The &hellip;","og_url":"https:\/\/matribhumisamachar.com\/en\/2026\/03\/05\/cosmo-announces-strategic-rd-collaboration-to-advance-ai-based-detection-of-early-neoplasia-in-barretts-esophagus\/","og_site_name":"Matribhumi Samachar English","article_published_time":"2026-03-05T06:58:56+00:00","article_modified_time":"2026-03-20T03:57:29+00:00","og_image":[{"url":"https:\/\/api.newsfilecorp.com\/newsinfo\/286350\/511"}],"author":"Saransh Kanaujia","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Saransh Kanaujia","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/matribhumisamachar.com\/en\/2026\/03\/05\/cosmo-announces-strategic-rd-collaboration-to-advance-ai-based-detection-of-early-neoplasia-in-barretts-esophagus\/","url":"https:\/\/matribhumisamachar.com\/en\/2026\/03\/05\/cosmo-announces-strategic-rd-collaboration-to-advance-ai-based-detection-of-early-neoplasia-in-barretts-esophagus\/","name":"Cosmo Announces Strategic R&amp;D Collaboration to Advance AI-Based Detection of Early Neoplasia in Barrett's Esophagus - Matribhumi Samachar English","isPartOf":{"@id":"https:\/\/matribhumisamachar.com\/en\/#website"},"datePublished":"2026-03-05T06:58:56+00:00","dateModified":"2026-03-20T03:57:29+00:00","author":{"@id":"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1"},"breadcrumb":{"@id":"https:\/\/matribhumisamachar.com\/en\/2026\/03\/05\/cosmo-announces-strategic-rd-collaboration-to-advance-ai-based-detection-of-early-neoplasia-in-barretts-esophagus\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/matribhumisamachar.com\/en\/2026\/03\/05\/cosmo-announces-strategic-rd-collaboration-to-advance-ai-based-detection-of-early-neoplasia-in-barretts-esophagus\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/matribhumisamachar.com\/en\/2026\/03\/05\/cosmo-announces-strategic-rd-collaboration-to-advance-ai-based-detection-of-early-neoplasia-in-barretts-esophagus\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/matribhumisamachar.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cosmo Announces Strategic R&amp;D Collaboration to Advance AI-Based Detection of Early Neoplasia in Barrett&#8217;s Esophagus"}]},{"@type":"WebSite","@id":"https:\/\/matribhumisamachar.com\/en\/#website","url":"https:\/\/matribhumisamachar.com\/en\/","name":"Matribhumi Samachar English","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/matribhumisamachar.com\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1","name":"Saransh Kanaujia","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g","caption":"Saransh Kanaujia"},"description":"Saransh Kanaujia is currently editor of Matribhumi Samachar Group. He earlier worked with Hindusthan Samachar News Agency. He is also associated with many organizations.","sameAs":["https:\/\/matribhumisamachar.com\/en"],"url":"https:\/\/matribhumisamachar.com\/en\/author\/matribhumisamachar\/"}]}},"_links":{"self":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/63430","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/comments?post=63430"}],"version-history":[{"count":1,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/63430\/revisions"}],"predecessor-version":[{"id":63725,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/63430\/revisions\/63725"}],"wp:attachment":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/media?parent=63430"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/categories?post=63430"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/tags?post=63430"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}